Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits from SPRINT (Systolic Blood Pressure Intervention Trial)

Circulation: Cardiovascular Quality and Outcomes

Volumn 10, Issue 4, 2017, Pages

  Patel, Krishna K ^a   Arnold, Suzanne V ^a   Chan, Paul S ^a   Tang, Yuanyuan ^a   Pokharel, Yashashwi ^a   Jones, Philip G ^a   Spertus, John A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

acute kidney injury; adult; blood pressure; decision making; hypertension

Indexed keywords

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHARED DECISION MAKING; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; CLINICAL DECISION MAKING; DECISION SUPPORT SYSTEM; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ANTIHYPERTENSIVE AGENT;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CLINICAL DECISION-MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PATIENT SELECTION; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 85018634298     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.117.003624     Document Type: Article

References (23)

1. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol. 2016;67:463-472. doi: 10.1016/j.jacc.2015.10.037.
2. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard bloodpressure control. N Engl J Med. 2015;373:2103-2116. doi: 10.1056/ NEJMoa1511939.
3. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18. doi: 10.1186/1471-2288-6-18.
4. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85. doi: 10.1186/1745-6215-11-85.
5. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK; SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-546. doi: 10.1177/1740774514537404.
6. Harrell FE. Regression Modeling Strategies, With Applications to Linear Models, Survival Analysis and Logistic Regression. Springer; 2001.
7. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Ijcai. 1995;14:1137-1145.
8. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774-781.
9. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585. doi: 10.1056/NEJMoa1001286.
10. Steyerberg E. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Springer Science & Business Media; 2008.
11. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; ISBN 3-900051-07-0. Available at: http://www.R-project.org/. 2013.
12. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831-841. doi: 10.1001/jama.2009.205.
13. Richardson WC, Berwick DM, Bisgard J, Bristow L, Buck C, Cassel C. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.
14. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
15. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christianson TJ, Mullan RJ, Smith SA. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167:1076-1082. doi: 10.1001/archinte.167.10.1076.
16. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med. 2013;368:6-8. doi: 10.1056/NEJMp1209500.
17. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54:1827-1834. doi: 10.1016/j.jacc.2009.05.073.
18. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individualpatient data. Ann Intern Med. 2002;136:438-448.
19. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, Leonetti G, Tuomilehto J, Yodfat Y. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167:1884-1891. doi: 10.1001/archinte.167.17.1884.
20. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
21. van Onzenoort HA, Menger FE, Neef C, Verberk WJ, Kroon AA, de Leeuw PW, van der Kuy PH. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58:573-578. doi: 10.1161/HYPERTENSIONAHA.111.171074.
22. McCormick BB, Hiremath S, Ruzicka M. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2016;374:2291-2292. doi: 10.1056/NEJMc1602668#SA4.
23. Basu S, Sussman JB, Hayward RA. Detecting heterogeneous treatment effects to guide personalized blood pressure treatment: a modeling study of randomized clinical trials. Ann Intern Med. 2017;166:354-360.